Reinspection lands Alexion with 483 for Soliris plant

Reinspection lands Alexion with 483 for Soliris plant

A US FDA reinspection of Alexion’s Rhode Island facility hit with a warning letter last year has resulted in a Form 483 with three observations.

The Smithfield, Rhode Island facility is owned and operated by Alexion as one of three plants that manufacture the human monoclonal antibody drug Soliris (eculizumab) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

In March 2013, the facility was hit by a US Food and Drug Administration (FDA) warning letter after six lots of the API for the drug were found to be contaminated with the bacteria Bacillus thuringiensis and the microorganism Acinetobacter radioresistens.

Since then the firm has issued several recalls of what - at approximately $600,000 per patient per year - is the world’s most expensive drug, but last month CEO Leonard Bell told investors during Alexion’s second quarter results the firm was awaiting a reinspection following “continued improvements” at the site.

However, according to a statement sent to Biopharma-Reporter.com by spokesman Irving Adler, the facility was reinspected by the FDA during the week of August 18, which issued a Form 483 with three inspectional observations, none of which were repeat observations from the original warning letter.

The three observations include a need for enhanced training around gowning procedures, more frequent environmental monitoring, and processes related to identification of the definitive root cause of a prior bioburden excursion,” we were told.

We continue to manufacture products, including Soliris, in Smithfield and other facilities,” he continued, “and we believe that the supply of Soliris to patients will not be interrupted.”

The two other facilities making Soliris are operated by Lonza in agreements that stretch until 2019.

We contacted the Switzerland-based contract manufacturing organisation (CMO) to ask if Soliris capacity has been increased on the back of Alexion’s manufacturing problems, but a spokesman told us the firm was “not in a position to comment,” on this or the process involved in making the MAb.

However, according to Alexion’s 2013 annual report, the “manufacture of Soliris is difficult” as it “requires a multi-step controlled process and even minor problems or deviations could result in defects or failures.”

Related News

NICE recommends Alexion's orphan mAb drug Soliris

NICE result for Soliris, but no justification for high manufacturing costs

Highly Specialised Tech programme used to recommend Soliris, says NICE

Highly Specialised Tech programme used to recommend Soliris, says NICE

These five vials of Soliris will cost the UK's NHS £15,750

Soliris first drug recommended through NICE's specialised tech unit

Alexion makes the mAb Soliris, one of the most expensive drugs in the world

Alexion growing biologics network through €450m Irish plant

Robert Fish spent 33 years at FDA in increasingly senior inspectorate roles

Ex-FDA inspector: How to avoid 483 observations during your next facility audit

Alexion's HQ in Ireland

Lonza take note: Alexion looking to bring more manufacturing in-house

iStock/CharlieAJA

Amgen developing Soliris biosimilar

More Manufacturing Issues Lead to Alexion Recall

More Manufacturing Issues Lead to Alexion Recall

Alexion buys Irish vialling facility to support Soliris manufacture

Alexion buys Irish vialling facility to support Soliris manufacture

Alexion's Ireland Headquarters

Another Soliris recall as Alexion evaluates its manufacturing network

Alexion announces third Irish facility

Alexion announces third Irish facility

FDA Releases Alexion Response to Form 483 on Microbial Contaminations

FDA Releases Alexion Response to Form 483 on Microbial Contaminations

US FDA Rebukes Alexion, Pfizer Italian Subsidiary in Warning Letters

US FDA Rebukes Alexion APIs, Pfizer Italian Subsidiary in Warning Letters

Soliris would cost the UK's health service £340,000 per patient per year

Alexion quizzed over Soliris' $567,000 price by NICE

Outside the NICE offices in London, UK

Alexion gives NICE requested Soliris info ahead of July review